Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin Expression

Background: Around 5% of all cutaneous squamous cell carcinoma (cSCC) metastasise. Metastases usually locate in regional skin and lymph nodes, suggesting collective cancer invasion. The cellular level of tumour invasion and prognostic parameters remain to be characterised. Methods: We performed immunohistochemical analyses of E-cadherin (marker for collective cancer invasion) and podoplanin (marker for epithelial-mesenchymal transition [EMT], single-cell invasion) expression in 102 samples of metastatic and non-metastatic cSCC and 18 corresponding skin and lymph node metastases to characterise the invasion of cSCC. Immunohistochemical results were retrospectively correlated with clinical data. Results: E-cadherin was highly expressed in metastatic and non-metastatic cSCC and skin metastases. This suggests collective cancer invasion. However, E-cadherin was downregulated in poorly differentiated cSCC and lymph node metastases, suggesting partial EMT. Podoplanin was significantly upregulated in metastatic (p = 0.002) and poorly differentiated (p = 0.003) cSCC. Overexpression of podoplanin represented a statistically independent prognostic factor for disease-free survival (p = 0.014). Conclusion: Collective cancer invasion is likely in cSCC. In lymph node metastases and poorly differentiated cSCC, partial EMT is possible. Podoplanin is an independent prognostic parameter for metastasis.

[1]  I. Zalaudek,et al.  Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. , 2015, European journal of cancer.

[2]  M. Beyer,et al.  Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma , 2015, The British journal of dermatology.

[3]  A. Khachemoune,et al.  Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends , 2015, International journal of dermatology.

[4]  P. Golusiński,et al.  Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma , 2014, European Archives of Oto-Rhino-Laryngology.

[5]  Juan Li,et al.  Podoplanin: a novel regulator of tumor invasion and metastasis , 2014, Medical Oncology.

[6]  Jia-qi Chen,et al.  Immunolocalization of Vimentin, Keratin 17, Ki-67, Involucrin, β-Catenin and E-Cadherin in Cutaneous Squamous Cell Carcinoma , 2014, Pathology & Oncology Research.

[7]  A. G. de Herreros,et al.  Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. , 2013, Journal of dermatological science.

[8]  J. Carucci,et al.  Skin Cancer in Immunosuppressed Patients , 2013, Facial Plastic Surgery.

[9]  A. Hauschild,et al.  Brief S2k guidelines – Cutaneous squamous cell carcinoma , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[10]  Jiali Han,et al.  Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. , 2013, Journal of the American Academy of Dermatology.

[11]  A. Qureshi,et al.  Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. , 2013, JAMA dermatology.

[12]  C. Mauch,et al.  Podoplanin expression in cutaneous head and neck squamous cell carcinoma—prognostic value and clinicopathologic implications , 2013, Journal of surgical oncology.

[13]  S. Mojal,et al.  D2-40 immunohistochemical overexpression in cutaneous squamous cell carcinomas: a marker of metastatic risk. , 2012, Journal of the American Academy of Dermatology.

[14]  C. Farah,et al.  Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation. , 2012, Oral oncology.

[15]  P. Friedl,et al.  Classifying collective cancer cell invasion , 2012, Nature Cell Biology.

[16]  H. Breuninger,et al.  Comparison and evaluation of the current staging of cutaneous carcinomas , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[17]  J. Leonardi-Bee,et al.  A systematic review of worldwide incidence of nonmelanoma skin cancer , 2012, The British journal of dermatology.

[18]  A. Carvalho,et al.  Prognostic and Risk Factors in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma of the Trunk and Extremities , 2011, Journal of skin cancer.

[19]  C. Schmults,et al.  Management of high-risk cutaneous squamous cell carcinoma. , 2010, The Journal of clinical and aesthetic dermatology.

[20]  M. Schmelz,et al.  Prognostic criteria for squamous cell cancer of the skin. , 2010, The Journal of surgical research.

[21]  D. Cassarino,et al.  Immunohistochemical Expression of D2-40 in Benign and Malignant Sebaceous Tumors and Comparison to Basal and Squamous Cell Carcinomas , 2008, The American Journal of dermatopathology.

[22]  Suzanne M Olbricht,et al.  Cutaneous squamous cell carcinoma. , 2008, Advances in dermatology.

[23]  B. Schönfisch,et al.  Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. , 2008, The Lancet. Oncology.

[24]  M. O’Banion,et al.  Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism. , 2007, Cancer research.

[25]  A. Weinberg,et al.  Metastatic Cutaneous Squamous Cell Carcinoma: An Update , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[26]  Jeffrey E. Lee,et al.  Invasive Squamous Cell Carcinoma of the Skin: Defining a High-Risk Group , 2006, Annals of Surgical Oncology.

[27]  G. Christofori,et al.  Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. , 2006, Cancer cell.

[28]  Victor Prieto,et al.  Lymph Node Metastases from Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2005, The Laryngoscope.

[29]  M. Detmar,et al.  Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. , 2005, The American journal of pathology.

[30]  H. Trau,et al.  Expression of E-Cadherin and Beta-Catenin in Cutaneous Squamous Cell Carcinoma and its Precursors , 2004, The American Journal of dermatopathology.

[31]  Sate H Hamza,et al.  Histologic Features in Primary Cutaneous Squamous Cell Carcinomas in Immunocompromised Patients Focusing on Organ Transplant Patients , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[32]  A. Katalinic,et al.  Epidemiology of cutaneous melanoma and non‐melanoma skin cancer in Schleswig‐Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer) , 2003, The British journal of dermatology.

[33]  H. Beug,et al.  Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis , 2003, Nature Reviews Molecular Cell Biology.

[34]  B. Smoller,et al.  Reporting tumor thickness for cutaneous squamous cell carcinoma , 2002, Journal of cutaneous pathology.

[35]  J. Thiery Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[36]  W. Dinjens,et al.  E‐cadherin—catenin cell—cell adhesion complex and human cancer , 2000, The British journal of surgery.

[37]  Y. Mitsuhashi,et al.  An Immunohistochemical Study of E‐Cadherin Expression in Human Squamous Cell Carcinoma of the Skin , 1999, The Journal of dermatology.

[38]  C. Cockerell,et al.  Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis , 1997, Cancer.

[39]  R. Carroll,et al.  Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. , 1992, Journal of the American Academy of Dermatology.

[40]  N. Swanson,et al.  Squamous cell carcinoma of the skin (excluding lip and oral mucosa). , 1992, Journal of the American Academy of Dermatology.

[41]  S. Frankel,et al.  Non-melanoma Skin Cancer , 2021, Surgical Oncology Manual.

[42]  S. Pollack,et al.  Metastases from squamous cell carcinoma of the skin and lip , 1989 .